Dynamic Technology Lab’s CytomX Therapeutics CTMX Stock Holding History

Dynamic Technology Lab’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-20,978	Closed	-$162K	–	1195
2021 Q1	$162K	Buy	+20,978	New	+$166K	0.02%	981
2020 Q4	–	Sell	-17,660	Closed	-$117K	–	1053
2020 Q3	$117K	Buy	17,660 +6,452	+58%	+$47.9K	0.02%	880
2020 Q2	$93K	Buy	+11,208	New	+$104K	0.01%	892
2019 Q4	–	Sell	-23,998	Closed	-$177K	–	1033
2019 Q3	$177K	Buy	+23,998	New	+$237K	0.03%	840
2018 Q2	–	Sell	-17,178	Closed	-$488K	–	1046
2018 Q1	$488K	Buy	+17,178	New	+$490K	0.07%	500
2017 Q4	–	Sell	-38,485	Closed	-$699K	–	1060
2017 Q3	$699K	Buy	+38,485	New	+$600K	0.11%	308
2017 Q2	–	Sell	-11,956	Closed	-$206K	–	1066
2017 Q1	$206K	Buy	+11,956	New	+$157K	0.05%	783

Other funds holding CTMX

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Dynamic Technology Lab's CTMX Position: Q2 2021 in Review

Dynamic Technology Lab sold out of CytomX Therapeutics (CTMX) in Q2 2021, closing a stake of 20,978 shares — an estimated $162K sold.

Dynamic Technology Lab first reported a position in CTMX in Q1 2017 and held it in 7 quarters. The position peaked at $699K in Q3 2017. 122 funds tracked by Wall St. Rank hold CTMX as of Q2 2021.

Dynamic Technology Lab reported no remaining CytomX Therapeutics position as of Q2 2021 after selling out during the quarter.
Dynamic Technology Lab sold 20,978 CytomX Therapeutics shares in Q2 2021, an estimated $162K.
Dynamic Technology Lab first reported a position in CytomX Therapeutics in Q1 2017 and held it in 7 quarters.
Dynamic Technology Lab's CytomX Therapeutics position peaked at $699K in Q3 2017.
122 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2021.

Based on Dynamic Technology Lab's 13F filing for Q2 2021, filed 13 Aug 2021.